Manuel Litchman, MD

Manuel Litchman, MD, the president, chief executive officer, and director of Mustang Bio, discussed upcoming research on MB-101 cell therapy.

The chief technology and chief executive officer of Mustang Bio discussed the company’s integrated approach to drug development.

Manuel Litchman, MD, the president, chief executive officer, and director of Mustang Bio discussed the company’s lead and second program.

The president, chief executive officer, and director of Mustang Bio discussed the company’s pipeline.

Manuel Litchman, MD, President and CEO of Mustang Bio Inc, highlights the advantages of using CAR-T therapies as treatments for rare cancers.